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Prostate cancers ability to invade and grow in bone marrow stroma is thought to be due in part to degradative enzymes. The
formation of prostate skeletal metastases have been reproduced in vitro by growing co-cultures of prostatic epithelial cells in
bone marrow stroma. Expression of urokinase plasminogen activator, matrix metalloproteinase 1 and 7 by prostatic epithelial
cells were identiﬁed using immunocytochemistry. Also, in vivo tissue sections from human prostatic bone marrow metastases
were stained. To establish the role of these enzymes on colony formation, inhibitory antibodies directed against urokinase
plasminogen activator, matrix metalloproteinase 1 and matrix metalloproteinase 7 were added into primary prostatic epithelial
cells and bone marrow stroma co-cultures. All prostatic epithelial cell cultures stained positively for matrix metalloproteinase 1,
matrix metalloproteinase 7 and urokinase plasminogen activator. Generally prostatic epithelial cells derived from malignant
tissues showed increased staining in comparison to epithelia derived from non-malignant tissue. In agreement with in vitro co-
cultures, the in vivo tissue sections of prostate bone marrow metastases showed positive staining for all three enzymes.
Inhibition studies demonstrated that blocking matrix metalloproteinase 1, matrix metalloproteinase 7 and urokinase
plasminogen activator function reduced the median epithelial colony area signiﬁcantly in bone marrow stroma co-cultures in
vitro. Using a human ex-vivo model we have shown that matrix metalloproteinase 1, matrix metalloproteinase 7 and urokinase
plasminogen activator play an important role in the establishment of prostatic epithelial cells within bone marrow.
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Prostate cancer (CaP) is the second commonest cancer in males in
the UK with 9500 deaths in 1999 (CRC, 2001/2002) and commonly
metastasises to the bone marrow (Jacobs, 1983). Fifty per cent of
patients who present clinically with CaP already have incurable
bone marrow metastases (George, 1988) and morbidity and death
is usually a direct consequence of these. Therefore it is of impor-
tance that the mechanisms involved in the metastatic process be
understood.
Tumour cells need to penetrate the extra-cellular matrix (ECM)
and basement membrane in order to metastasise. The major
components of the ECM are collagens (types I-V), proteoglycans,
elastin, laminin and ﬁbronectin, and in order to break free from
the primary site and invade at the secondary site, tumour cells
must overcome these structural barriers (Woolley, 1993). In recent
years the interactions of various proteases have been identiﬁed in
this crucial step, including the matrix metalloproteinase (MMP)
and the serine protease family (plasmin and urokinase plasminogen
activator (uPA)). The relative contributions of these proteases in
tumour cell invasion has been in debate. More recent data have
implicated the MMP family in a more complex role than ECM
degradation alone. They have also been found to be actively
involved with generating factors that can stimulate tumour cell
(Stetler-Stevenson and Yu, 2001) and endothelial migration and
angiogenesis needed for tumour formation (John and Tuszynski,
2001). The matrix metalloproteinase family comprises at least 20
zinc dependent endopeptidases clearly identiﬁed, with more (up
to MMP-26) currently being characterised (Marchenko et al,
2001). Normally they are associated with programmed cellular
events such as tissue remodelling, wound healing, uterine and
breast involution and organogenesis in development (Chambers
and Matrisian, 1997). Originally members of the MMP family were
thought to be substrate speciﬁc. However, it has been recognised
that each can degrade multiple substrates (John and Tuszynski,
2001).
In this study we looked at speciﬁc proteases that could be active
in CaP and its secondary metastatic site, the bone marrow. MMP-7
(matrilysin) exhibits high activity against collagen IV, a major
component of bone marrow stroma (BMS) and other basement
membranes and has been found previously in carcinoma cells of
many cancers including prostate and their metastases (Pajouh et
al, 1991). In contrast, MMP-1 (interstitial collagenase) has a high
substrate afﬁnity for collagen I, also a major component of BMS
(Takahashi et al, 1994). MMP-1 is thought to be expressed mainly
by ﬁbroblasts/stromal cells and is involved with interactions
between the tumour cells and host ﬁbroblasts in the remodelling
of the ECM (Heppner et al, 1996). MMP-1 production has also
been found to be up-regulated during cell–cell contact with breast
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Urokinase plasminogen activator is also found in human primary
prostate carcinomas and in bone metastases (Kirchheimer et al,
1985). Data obtained from a limited number of cell lines have indi-
cated that uPA is associated with the more aggressive type of
carcinoma and facilitates invasion (Hoosein et al, 1991; Festuccia
et al, 1998). These proteases are therefore of particular interest in
the metastatic development of prostate cancer.
As yet, no human model has been established to study variations
in expression and effects of MMP-1, MMP-7 and uPA on the
formation of prostate bone metastases in vitro. The prostatic
epithelial cell (PEC)/BMS co-culture system as described by Lang
et al (1998) represents an ideal in vitro model for this purpose.
Here, we propose that enzyme mediated cell interactions maybe
important for the expansion of epithelial colonies within BMS.
MATERIALS AND METHODS
Materials
All reagents were purchased from Sigma-Aldridge, Poole, UK. All
tissue culture medium and horse serum was from Life Technolo-
gies, Paisley, UK with the exception of Ham’s F12 media, PAA
Laboratories, Austria. Foetal calf serum (FCS) was supplied by Sera
Labs, Sussex, UK and Worthington collagenase type 1 and trypsin
from Lorne Laboratories Ltd., Twyford, UK.
Antibodies
MMP-7 and uPA were from Chemicon International, Harrow, UK;
MMP-1 and mouse IgG1 from R&D Systems, Abingdon, UK;
mouse anti-human pan cytokeratin from Sigma-Aldridge, Poole,
UK; rabbit anti-human pan cytokeratin from Biogenesis Ltd.,
Poole, UK; rabbit anti mouse biotinylated antibody, swine anti-
rabbit TRITC and aqueous mounting medium from DAKO Ltd.,
Cambridge, UK. Vectastain Elite ABC kit from Vector Laboratories,
CA, USA and streptavidin Alexa Fluor
1 488 was from Molecular
Probes, Oregon, USA.
Cell lines
The malignant prostate cell line PC-3 (bone marrow metastasis
derived) (Kaighn et al, 1979) and non-malignant line PNT2-C2
(Berthon et al, 1995) were cultured in Ham’s F12, 7% FCS and
2m M L-glutamine and in RPMI 1640, 10% FCS and 2 mM L-
glutamine respectively. Cultures were grown at 378C in a humidi-
ﬁed atmosphere of 5% CO2 in air.
Primary tissue collection and culture
With informed consent prostatic tissue was obtained from males
undergoing treatment for malignant (CaP) or non-malignant
benign prostatic hyperplasia (BPH) disease. Each individual pros-
tate chip was bisected with half undergoing histological analysis
for diagnostic evaluation and the remainder used for tissue culture.
Prostate epithelia and ﬁbroblasts were isolated by collagenase diges-
tion followed by differential centrifugation as described (Lang et al,
1998). Epithelial cells were initially grown in ﬂasks and then used
at passage 1–3.
Human ribs removed for access during routine renal surgery
were prepared for tissue culture using the method of Coutinho
et al (1993). Bone marrow cells were ﬂushed out from the rib
and were resuspended in long-term culture medium (Iscove’s
Modiﬁed Dulbecco’s Medium containing 10% FCS, 10% horse
serum and 5610
77 M hydrocortisone) and 2610
7 cells plated into
25 cm
2 tissue culture ﬂasks. The cultures were grown at 338Ci n
5% CO2 in air for 4–5 weeks until haemopoietically active areas
were observed.
Co-culture experiments
Bone marrow stromal cultures were trypsinised (0.5% trypsin) and
re-seeded into 24-well culture plates (or 4-well glass slide ﬂask) at
the same cell density and incubated for 48 h.
The media on the BMS was removed and replaced with long-
term culture medium plus Keratinocyte-SFM (1:3) containing
500 epithelial cells (PC-3, PNT2-C2 or primary PEC) per well.
The co-cultures were incubated for 7–10 days at 378C then ﬁxed
with methanol/acetone (1:1), allowed to dry and frozen at
7208C until required.
Immunocytochemistry
Samples were incubated with primary antibodies overnight at 48C
in a humidiﬁed chamber after blocking with 10% serum then 0.3%
hydrogen peroxide. Anti-MMP-7, anti-uPA, anti-MMP-1 and
mouse IgG1 were prepared at 20 mgm l
71 and mouse anti-human
pan cytokeratin at 1:200. This was followed by addition of bio-
tinylated rabbit anti mouse 1:400 for 40 min at room temperature.
A complex of avidin DH and biotinylated horseradish peroxidase
H (Vectastain Elite ABC kit) was then added for 15–20 min,
followed by the addition of DAB substrate for 5–10 min. After
washing with distilled water the cells were counterstained using
haematoxylin and ﬁxed in aqueous mounting ﬂuid. Samples were
scored as to the intensity of brown staining: (7) blue haematoxy-
lin counterstain visible only, (7/+) pale brown, (+) brown, (++)
dark brown. These staining intensities were set using agreed criteria
and results were corroborated with more than one investigator.
For dual ﬂuorescent staining, cultures were ﬁxed, blocked and
labelled for primary antibodies as observed above. Rabbit anti-
human cytokeratin (1:100) was added for 30 min, followed by a
swine anti-rabbit TRITC (1:20) for 1 h in the dark. The samples
were blocked for 30 min using PBS/10% rabbit serum and 1%
BSA, then incubated with rabbit anti-mouse biotinylated antibody
(1:400) for 30 min. After washing, streptavidin Alexa Fluor
1 488
(5 mgm l
71) was added for 1 h in the dark.
Cells were observed using an Olympus BX51 upright micro-
scope, with a Plan-Apochromat 406 objective (NA 1.0, oil
immersion). Using a triple-band bypass ﬁlter (Chroma Technology
Corp. set: 61000 v2SBX for DAPI/FITC/TRITC) the interaction of
TRITC/Cytokeratin (ex.542 nm em.560 nm), FITC/uPA, MMP-1,
MMP-7 (ex.488 nm em.505–530 nm) and DAPI (ex.360 em.460)
were examined. Images were captured via a cooled Colourview
12 and the analySIS imaging acquisition and processing system
(SiS, GmbH). Images were captured at 130061030, 24 bit resolu-
tion with an exposure time of 5 s. Processing and montaging of
images was then carried out using Adobe PhotoShop 6.0 (Adobe
Systems Inc.)
Immunohistochemistry
Prostatic bone marrow metastases were sectioned from 8 mm
trephine core biopsies taken from the iliac crest of patients with
untreated prostate cancer. The undecalciﬁed parafﬁn embedded
sections were ﬁrst de-waxed in two changes of xylene for 5 min,
then run through a series of alcohols to rehydrate the sections.
Sections were immersed in citrate solution pH 6.0 and placed in
a microwave on full power for 25 min. The solution was allowed
to cool and was exchanged for water. Samples were stained and
scored according to protocols shown above.
Inhibition studies
Primary epithelial cell/BMS co-cultures were set up as above, in
addition to which the epithelial cells were initially allowed to bind
to the BMS for 4 h at 378C before antibodies against either uPA,
MMP-1 and MMP-7 (functionally blocking) were added at 2 mg
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71 daily. Mouse IgG1 was added to the control well. After 7
days at 378C the cultures were ﬁxed using methanol/acetone
(1:1), dried then immunostained for cytokeratin. Colony areas
were measured using an eyepiece graticule after calibration with
a slide graticule. For each well 4100 colonies were measured for
length and width. The median colony area per well was then calcu-
lated and statistical analysis achieved using Wilcoxon’s Rank Sum
Test.
RESULTS
Epithelial colony morphology and enzyme characterisation
in BMS co-culture
The cell lines PC-3, PNT2-C2 (derived from normal prostate), and
primary epithelial cells (derived from patients with CaP or BPH)
were initially grown on BMS and stained for cytokeratin to observe
colony morphologies. As a comparison to the malignant cell line
PC-3, the PNT2-C2 cell line was used to represent normal prostate
cell behaviour. We also used primary PEC derived from patients
with CaP and compared them to BPH derived epithelial cells.
Figure 1 (CK) shows the appearances of the different epithelial cells
grown on BMS and labelled with cytokeratin. Primary epithelial
cells derived from patients with CaP grew colonies that appeared
either spiky or round and compact. Epithelial cells derived from
patients with BPH always formed round and compact colonies.
Retraction of the BMS was also seen with cells derived from
CaP. Cell lines showed dispersed PC-3 colonies but compact
PNT2-C2 colonies.
Co-cultures were also dual-stained for cytokeratin, and either
MMP-1, MMP-7 or uPA to establish that prostate epithelial colo-
nies produce these enzymes in BMS. Epithelial cells derived from
CaP stained positively for MMP-1 and MMP-7 when grown in
BMS co-culture (Figure 1). Some of the bone marrow stroma at
the interface with the PEC (orange/yellow) had retracted away
and showed intense MMP-1 green staining (arrows). Urokinase
plasminogen activator staining was positive but less intense. Colo-
nies from BPH derived epithelial cells showed staining of MMP-1,
MMP-7 and uPA located within the PEC with less marked staining
towards the edge of the colony.
Co-cultures of the cell lines showed that all three enzymes were
observed throughout the PC-3 cells. This co-localised with cytoker-
atin at the cell membrane/pseudopodial processes. The PNT2-C2
cell line showed some weak cytoplasmic staining for all the
enzymes, but they were predominantly cytokeratin positive.
To compare the presence of MMP-1, MMP-7 or uPA when
epithelial cells (cell lines and primaries) were grown on tissue
culture plastic or normal human BMS, cultures were immuno
stained, using DAB. The results summarised in Table 1 showed that
the PC-3 cell line expressed strong staining for all the enzymes
tested on plastic, except MMP-1, but this was up-regulated in
the presence of BMS. The non-malignant cell line PNT2-C2
demonstrated absent or low staining intensities for all the enzymes
on plastic but showed up-regulation of MMP-1 and uPA on BMS,
with uPA staining the most. Primary PEC cultures from patients
with CaP showed positive staining for all the enzymes on plastic,
which was more intense than in the cells derived from BPH. There
was no difference in staining between CaP and BPH on BMS for
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Figure 1 Enzyme characterisation of primary prostate epithelial cells and the prostate cell lines grown with BMS. Immunocytochemical staining showing
typical colonies of cytokeratin (CK) positive (DAB brown staining) and ﬂuorescent dual staining of epithelial cells grown in BMS co-culture (each picture is
unrelated). Enzyme stained photographs are shown as dual ﬂuorescence: red=cytokeratin; green=location of either uPA, MMP-1 or MMP-7; yellow=double
staining; blue=DAPI nuclear counterstain (n=5). All negative controls were black. Arrows indicate retracted stromal edge.
Proteolytic enzymes and prostate bone metastasis
CA Hart et al
1138
British Journal of Cancer (2002) 86(7), 1136–1142 ã 2002 Cancer Research UKMMP-7 and uPA. However, MMP-1 expression was greater in CaP
derived cells compared to BPH. These results were consistent in
several primary and cell line cultures.
Enzyme characterisation of bone marrow metastases
Using bone marrow metastasis sections from patients with CaP it
was possible to compare the staining pattern of the enzymes in vivo
to the in vitro model. These sections were previously identiﬁed as
prostatic bone marrow metastases by positive PSA staining (Bryden
et al, 2002). Figure 2 shows immunohistochemical (DAB) staining
for MMP-1, MMP-7 and uPA using the same concentration of
antibody as for the co-culture staining. Serial sectioning allowed
comparison of the different enzyme staining patterns within the
same area of tissue. Areas of cytokeratin positive epithelial cells
within the bone marrow structure can be seen in Figure 2B. The
epithelial colonies showed high expression of MMP-1 (C) and
MMP-7 (D), with less intense staining in the surrounding stroma.
Figure 2E showed weaker staining for uPA than was observed for
MMP staining, but again this was more clearly stained in the
epithelial region than the stromal area.
Prostate bone metastases (n=7) were sectioned and stained for
cytokeratin, MMP-1, MMP-7 and uPA. Median staining scores
were then calculated and summarised in Table 2. One sample
was cytokeratin negative but was identical in morphology to the
cytokeratin positive epithelia in the other samples. Generally
samples stained strongest for MMP-1, then MMP-7 and more
weakly for uPA. The staining intensity was strongest towards the
outer edges of the epithelial cells.
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Figure 2 Serial sections of a prostatic bone marrow metastasis. Typical examples of the enzyme staining found from seven samples (see Table 2). Each
photograph shows the same region of sample immunohistochemically (DAB) labelled for: (A) negative control (haematoxylin), (B) cytokeratin indicating the
colonies of epithelial cells within the bone marrow space, (C) MMP-1, (D) MMP-7 and (E) uPA.
Table 1 Immunocytochemical (DAB) staining for the proteolytic
enzymes in prostate epithelial cells derived from patients with either CaP
or BPH and in the PC-3 and PNT2-C2 cell lines grown either on plastic
or together with BMS as a co-culture
MMP-1 MMP-7 uPA
Plastic BMS Plastic BMS Plastic BMS
PC-3 + ++ ++ ++ ++ ++
PNT2-C2 77 /+ 7/+ 7/+ 7/+ +
CaP +/++ + + + + +
BPH + 7/+ 7/+ + 7/+ +
The staining intensity is equivalent to 7=negative, 7/+=weak positive (light brown),
+=positive (brown), ++=strong positive (dark brown). CaP n=4, BPH n=3 (median
score).
Table 2 Enzyme immunohistochemical (DAB) staining of prostatic bone
marrow metastasis sections
Sample MMP-1 MMP-7 uPA Cytokeratin
1+ + + + 7/+ 7/+
2+ + + + 7/+ ++
3+ + 7/+ ++
4+ + + 7/+ ++
5+ 7/+ 7 +
6+ 7/+ 7/+ ++
7+ + + 7/+ 7
Median ++ + 7/+ ++
Samples of seven undecalciﬁed prostatic bone metastases were cut and labelled with
the antibodies shown. Because of patient heterogeneity, the median staining score is
given at the bottom of the table. 7=negative staining; 7/+=weak positive (light
brown); +=positive (brown); ++=strong positive (dark brown).
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Functionally blocking antibodies against the proteolytic enzymes
were added to the in vitro co-culture system to further study the
role of these enzymes in epithelial colony formation. As the
enzymes are secreted continually by the epithelial or stromal cells,
antibodies were added daily. Titration of the antibodies indicated
that 2 mgm l
71 consistently and signiﬁcantly inhibited growth of
epithelial colonies (data not shown). Figure 3A shows the appear-
ance of typical BPH derived colonies after treatment with the
antibodies, cultures with samples derived from patients with CaP
showed a similar appearance. The control co-culture showed large
colonies, whereas the co-cultures treated with the blocking antibo-
dies showed smaller irregularly shaped colonies. Results were
similar whether epithelial cells were derived from benign or malig-
nant tissue. This experiment was repeated on primary epithelial cell
samples, derived from malignant (n=6) or benign tissue (n=7)
shown in Figure 3B,C. Patient samples varied in response to these
blocking antibodies, but overall, samples derived from patients
with CaP and BPH showed greatest reduction in colony area with
anti-MMP-7, followed by anti-MMP-1 then anti-uPA. Median per
cent reduction of colony area for CaP derived colonies compared
to the control was 48, 45 and 23%, with BPH derived colonies
48, 45 and 37% respectively. There was no signiﬁcant difference
observed between the responses for CaP or BPH derived epithelial
cells. However, statistical analysis showed signiﬁcantly reduced
(P50.05) colony growth after anti-MMP-1 was added to the
culture in 6/6 CaP samples and 6/7 BPH samples. Inhibiting
MMP-7 signiﬁcantly decreased (P50.05) colony size in 5/6 CaP
and 7/7 BPH samples and blocking uPA activity signiﬁcantly
reduced (P50.05) growth in 1/3 CaP and 4/4 BPH samples
(Wilcoxon’s Rank Sum Test) compared to the control.
The total numbers of colonies formed in the presence of the
antibodies was variable, either remaining the same or increasing
above that of the control (data not shown).
DISCUSSION
Prostate cancer shows a predilection to metastasise to the bone
marrow. We have used in vitro models (Lang et al, 1998) to iden-
tify potential enzymes involved in this process and compared these
with in vivo effects in human bone marrow metastasis sections.
Initially we looked at the colony morphology of PEC when
grown in BMS. The PC-3 cell line and cells derived from patients
with CaP showed colonies and cells which appeared spiky and scat-
tered whilst the PNT2-C2 cell line and cells derived from patients
with BPH showed rounded colonies. This conﬁrmed ﬁndings
previously reported (Lang et al, 2000) which suggests a more
motile and invasive nature of PC-3 and CaP derived epithelial cells.
Regarding proteolytic enzyme production in BMS co-culture, we
found that when cells derived from patients with CaP were grown
in BMS co-culture, not only were the epithelial cells strongly
stained for MMP-1, the stromal cells around the leading edge of
the colony were also strongly positive. This has been shown in
previous studies where in vivo MMP-1 expression was found in
the stromal area along the invasive margin in gastric cancer (Migita
et al, 1999) and breast cancer (Heppner et al, 1996). Also, in vitro
MMP-1 expression was up-regulated by cell–cell contact between
BMS and breast carcinoma cells (Saad et al, 2000). This may indi-
cate subtle tumour/stroma interactions causing increased secretion
of these enzymes. Epithelial cells derived from patients with BPH
showed enzyme staining similar to CaP derived cells but less was
seen at the stromal margins of these colonies, suggesting no stimu-
lation of the stromal cells to secrete these enzymes. Clearly
interactions between BMS and epithelial cells play an important
role in the level of enzyme expression.
Using immunocytochemistry we compared the enzyme levels
between the cell lines PC-3, PNT2-C2 and the primary PEC.
Previous studies showed that the PC-3 cell line expresses uPA
(Hoosein et al, 1991) and mRNA for 10 MMPs including MMP-
1 and MMP-7 (Giambernardi et al, 1998). We conﬁrmed that
the PC-3 cell line gave strong positive staining for uPA, MMP-1
and MMP-7. By comparison, the PNT2-C2 cell line gave weak
staining for these enzymes, which was marginally increased in
BMS co-cultures. For the primary PEC, median staining values
were shown due to patient variability. This phenomenon must
not be overlooked as differing enzyme expression between patients
could provide an insight into why prostate cancer can be highly
variable in its disease progression. Generally, primary samples from
patients with CaP stained more strongly for these enzymes than
samples derived from BPH when grown on tissue culture plastic.
However, apart from MMP-1 (increased staining for CaP in BMS
compared to BPH cells) we did not ﬁnd a difference between the
staining of CaP or BPH derived samples when grown in the
BMS co-culture. In support of this, it has been reported that both
CaP and BPH epithelial cells will grow and invade in BMS co-
culture in a similar way (Lang et al, 1998), despite the fact that
although BPH cells do not invade the bone marrow in vivo they
are released into the circulation during routine TURP for bladder
outﬂow obstruction (McIntyre et al, 2000, 2001). Therefore, subtle
differences in enzyme expression between CaP and BPH epithelial
cells could make a difference to these circulating cells in determin-
ing their ability to invade through endothelium and ultimately
grow in the bone marrow itself.
Our results indicated very subtle differences in enzyme expres-
sion between the CaP and BPH primary epithelial cells when
grown in BMS whereas in previous in vivo studies greater differ-
ences were observed. Hashimoto et al (1998) demonstrated a
signiﬁcant correlation between the levels of MMP-7 mRNA in
the primary prostate carcinoma and pathological stage and mean
serum levels of uPA were reported to be signiﬁcantly higher in
patients with CaP compared to healthy individuals or patients with
BPH (Miyake et al, 1999). However, no signiﬁcant correlation was
made in a study carried out to identify changes in blood plasma
levels of MMP-1 between patients with CaP or with BPH (Lein
et al, 1998).
Our in vivo staining of prostate bone marrow metastases from
patients with CaP showed positive staining for MMP-1 and
MMP-7 but less intense staining for uPA. Previous work has
demonstrated that MMP-1 levels in uncultured primary prostate
carcinoma are very low and variable (Varani et al, 2001), whereas
we have demonstrated that MMP-1 is strongly expressed in the
bone metastases of prostate cancer patients. Our in vitro data also
showed that in BMS co-culture, MMP-1 staining was greater in
CaP co-cultures compared to BPH co-cultures. This reiterates the
proposition that up-regulation of MMP-1 secretion maybe an
important factor in the formation of prostate bone marrow metas-
tases. As these changes in enzyme expression were subtle, further
work using zymography may clarify these results and give quanti-
tative data to corroborate our qualitative data.
Until now there has been no human in vitro model to demon-
strate the role of proteolytic enzymes on metastasis formation, and
there have been few studies to determine whether blocking these
enzymes causes signiﬁcant effect (although, previous animal models
have shown that rats inoculated with Dunning R 3227, Mat LyLu
rat prostate carcinoma cell line transfected to over-express uPA
developed hind limb paralysis much faster than transfectants which
under-expressed uPA (Achbarou et al, 1994)).
The BMS co-culture system was used as a human ex-vivo model
to study the effects of blocking enzyme activity on prostate epithe-
lial colony growth enabling direct observation of their importance
in the process of invasion. In most samples total median colony
area was reduced by around 50% following inhibition of MMP-1
and MMP-7. For uPA the reduction was less but still signiﬁcant.
In this study, cells from the primary tumour site rather than cells
from metastatic bone biopsies were grown. Kirchheimer et al
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Figure 3 Antibody inhibition of epithelial colony area (%). A comparison of the inhibition of prostate epithelial colony area in the presence of enzyme
antibodies was made for a variety of primary epithelial samples. Typical immunocytochemical (DAB) cytokeratin staining of a BPH epithelial cell/BMS co-
culture in the presence of non-speciﬁc mouse IgG1, anti-MMP-1, anti-MMP-7 and anti-uPA antibodies (2 mg day
71) after 7 days in culture is shown in (A).
Median area of 4100 colonies per sample were calculated and inhibition was calculated as a per cent of the control area. Median percentage inhibition is
represented by the bar: (B) CaP, MMP-1 and MMP-7 (n=6), uPA n=4; (C) BPH, MMP-1 and MMP-7 (n=7), uPA (n=3).
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their respective bone metastases, the bone metastases had 1.5 times
higher uPA than the corresponding primary tumour. For future
study it would be interesting to ascertain whether greater reduction
in colony size could be achieved by using prostate bone metastatic
cells in the BMS co-culture.
Blocking MMP enzyme function caused reduction in colony size
but not their number. Therefore, initial establishment of epithelial
colonies within BMS was not affected although the subsequent
growth and formation of these colonies was. Recent evidence has
revealed that the MMPs not only cause degradation of the ECM
but also interact with adhesion molecules and can stimulate cell
migration and invasion. What we observed may have been there-
fore the result of cell migration and colony formation failure due
to the neutralising effect of the antibodies (Stetler-Stevenson and
Yu, 2001).
In summary, we have used the in vitro BMS co-culture system to
show that MMP-1, MMP-7 and uPA are expressed by the bone
metastatic prostate cell line PC-3, primary CaP and BPH derived
epithelial cells. They are also up-regulated in the non-malignant
prostate cell line PNT2-C2 when grown within BMS. We have
demonstrated similar staining results using human prostate bone
marrow metastases sections in vivo conﬁrming the notion that in
vivo observations reﬂect events observed in vitro. Inhibiting these
enzymes reduced prostatic colony growth in the BMS, a ﬁnding
supporting the proposition that these enzymes are important in
development of metastases in humans. Our understanding of the
metastatic process regarding MMP involvement is still limited,
but clearly these enzymes play an important role in the invasion
of bone marrow stroma by prostatic epithelial cells and bone
marrow metastasis formation in man.
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